Abstract
The article considers the issues of differential diagnosis and treatment of endometrial hyperplasia without atypia in women of reproductive age with the use of different types of progestins. Estrogen, progesterone, marker differentiation, apoptosis, and paracrine markers of cellular interactions have been studied to predict the efficacy and causes of resistance to progestin therapy.
Publisher
European Scientific Platform (Publications)
Subject
General Agricultural and Biological Sciences
Reference12 articles.
1. Chandra, V., Kim, J. J., Benbrook, D. M., Dwivedi, A., & Rai, R. (2016). Therapeutic options for management of endometrial hyperplasia. Journal of gynecologic oncology, 27(1), e8. https://doi.org/10.3802/jgo.2016.27.e8/
2. Sanderson, P. A., Critchley, H. O., Williams, A. R., Arends, M. J., & Saunders, P. T. (2017). New concepts for an old problem: the diagnosis of endometrial hyperplasia. Human reproduction update, 23(2), 232–254. https://doi.org/10.1093/humupd/dmw042
3. Yang, Y. F., Liao, Y. Y., Peng, N. F., Li, L. Q., Xie, S. R., & Wang, R. B. (2012). Prediction of coexistent carcinomas risks by subjective EIN diagnosis and comparison with WHO classification in endometrial hyperplasias. Pathology, research and practice, 208(12), 708–712. https://doi.org/10.1016/j.prp.2012.08.009
4. Nees, L. K., Heublein, S., Steinmacher, S., Juhasz-Böss, I., Brucker, S., Tempfer, C. B., & Wallwiener, M. (2022). Endometrial hyperplasia as a risk factor of endometrial cancer. Archives of gynecology and obstetrics, 10.1007/s00404-021-06380-5. Advance online publication. https://doi.org/10.1007/s00404-021-06380-5
5. Georgescu, T. A., Cirstoiu, M., Costache, M., Lazaroiu, A., Dumitru, A., & Sajin, M. (2016). Histopathological, Immunohistochemical and Therapeutical Assessment of Premalignant Endometrial Lesions in a Hospital Based Series of Cases. Maedica, 11(2), 115–121.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献